Using direct targeting (anti-GD2) or immunostimulatory (anti-4-1BB) mAbs in a MRD setting was shown to increase survival significantly of tumor bearing TH-MYCN mice compared to single agents alone (Fig. 8B,C). This evidence concerns the gene MYCN and neoplasm.